News

Discovery of a novel and potent BRAF (V600E) inhibitor with a unique kinase targeting profile, EBI-907: pharmacological characterization and strategies to overcome drug resistance and paradoxical activation

2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics

Conference, October 19-23 in Boston, Massachusetts.

BRAFi EBI-907 poster for AACR-NCI-EORTC 2013.pptx